Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference
Dateline City:
WHITEHOUSE STATION, N.J.
Company Confirms Development Program for Investigational Once Daily (QD) Dosing Regimen of ISENTRESS
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is
presenting pharmacokinetic data this week on investigational
formulations of a once daily (QD) dose of ISENTRESS at the 14th
European AIDS Conference (EACS), sponsored by the European AIDS Clinical
Society. The meeting is currently taking place in Brussels, Belgium,
Oct. 16-19, 2013. The poster presentation A Single Dose Food Effect
Study of Raltegravir Formulations (Poster #PE10/17) will be
presented Thursday, Oct.
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news